Neonatal Infections with HSV

Neonatal infections with herpes simplex virus (HSV) were first reported in the mid-1930s, when Hass described the histopathologic findings of a fatal case and when Batignani reported a newborn with herpes simplex keratitis. Over the subsequent decades, the spectrum of disease which HSV can cause in the newborn has been detailed and the efficacy of antiviral therapy in neonatal HSV infections has been established.

The earliest antiviral agents with in vitro activity against HSV proved too toxic in humans to be useful. Vidarabine was the first systemically administered antiviral medication with activity against HSV for which the therapeutic efficacy outweighed its toxicity for the management of life-threatening HSV disease.

Licensed for use in the United States in 1977, vidarabine occupies a special place in the historical development of antiviral compounds. Due to toxicity when administered systemically, use of intravenous vidarabine was restricted by the Food and Drug Administration to life-threatening HSV and varicella-zoster virus infections.

Multicenter collaborative clinical trials established its efficacy in the treatment of neonatal HSV infections, HSV encephalitis, varicella-zoster virus infections, and herpes virus infections in immunocompromised patients. Such collaborative efforts not only established the scientific merit of the compound but also foreshadowed the system by which newer antiviral drugs such as acyclovir and the antiretroviral compounds are evaluated.

Additionally, close investigation of vidarabine provided detailed information about herpes virus infections at a cellular level, illuminating not only the natural history of the diseases but also molecular mechanisms of antiviral action. Intravenous vidarabine has not been available in the United States since 1992, although a topical preparation remains on the market for the treatment of HSV keratitis.

The next development in the management of neonatal HSV disease was a landmark comparison of vidarabine and a lower dose of acyclovir conducted during the 1980s. Most recently, a higher dose of acyclovir has been evaluated in the management of neonatal HSV disease. Each of these trials resulted in a change in the therapeutic standard for the management of neonatal HSV disease.

This powerful diagnostic tool has enhanced the ability to correctly diagnose neonatal HSV infections and has proven especially beneficial in patients without overt manifestations of HSV disease such as skin vesicles. It also has provided an additional means by which response to therapy can be assessed.

Other areas of promise with respect to prevention of neonatal HSV infections include the development of genetically engineered subunit and live attenuated HSV vaccines for prevention of maternal genital infections and evaluation of antiviral administration to gravid women to reduce the likelihood of clinically apparent genital disease at the time of delivery.

HSVCurative is a potent all natural antiviral cure for herpes, highly effective against HSV1 and HSV2; it has a wide spectrum of antiviral activity against these viruses, even for genital herpes. The cure in this treatment has the ability to inactivate and destroy HSV, which has been established in published clinical trials. It is to be applied directly to an outbreak.

HSVCurative is used specifically to treat HSV1 and HSV2 infections and acts as a curative agent against both these strains of herpes. It exhibits a pronounced anti-herpetic activity against HSV1 and HSV2 and, unlike other cures for herpes, actually kills these viruses upon exposure regardless of location on the body.

HSVCurative is formulated at maximum strength and has produced spectacular results above other potential herpes cures in eliminating herpes outbreaks in almost all known cases of use on herpes. It is possibly the most powerful and effective topical herpes treatment on the market, providing total clearance of outbreaks time after time.

Topical application causes herpes outbreaks to dissolve and dry out, with total clearance commonly experienced in 24 to 36 hours. This herpes cure gives immediate results and pain relief are certainly experienced with every application. To learn more, please go to http://www.bcured.net.